Analysis of United States Patent RE46363
United States Patent RE46363, titled "Combination of recombinant human tumor necrosis factor (TNF) receptor and methotrexate," claims a method of treating rheumatoid arthritis (RA) and other autoimmune diseases. The patent, originally filed on June 23, 2004, by Immunex Corporation and later assigned to Amgen Inc., was reissued on June 2, 2015. The core of the patent lies in the combination therapy involving etanercept, a soluble TNF receptor, and methotrexate.
What is the scope of United States Patent RE46363?
United States Patent RE46363 broadly claims a method for treating autoimmune diseases. The primary claims focus on the combined administration of a soluble tumor necrosis factor (TNF) receptor and methotrexate. Specifically, the patent covers:
- Claim 1: A method for treating a human with an autoimmune disease comprising administering to the human an effective amount of a combination comprising a recombinant human tumor necrosis factor (TNF) receptor and methotrexate. The patent defines "autoimmune disease" to include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
- Claim 2: The method of Claim 1, wherein the recombinant human TNF receptor is a fusion protein comprising the extracellular domain of a human TNF receptor p75 fused to an Fc portion of a human immunoglobulin G1 (IgG1). This definition directly corresponds to etanercept.
- Claim 3: The method of Claim 1, wherein the autoimmune disease is rheumatoid arthritis.
- Claim 4: The method of Claim 2, wherein the recombinant human TNF receptor is etanercept.
The patent details specific dosages and treatment regimens, emphasizing the synergistic effect of combining etanercept with methotrexate. It suggests that this combination results in greater efficacy in reducing disease activity and improving patient outcomes compared to monotherapy.
What is the technological basis of the patented invention?
The invention is based on the understanding of tumor necrosis factor (TNF) as a key inflammatory cytokine involved in the pathogenesis of several autoimmune diseases. TNF promotes inflammation and joint destruction in conditions like rheumatoid arthritis. Etanercept, a biopharmaceutical drug marketed as Enbrel, is a dimeric fusion protein that acts as a soluble TNF receptor. It binds to and neutralizes circulating TNF, thereby inhibiting its pro-inflammatory actions.
Methotrexate is a conventional disease-modifying antirheumatic drug (DMARD). While its exact mechanism in RA is not fully elucidated, it is known to have immunosuppressive and anti-inflammatory effects, partly through inhibition of dihydrofolate reductase and adenosine release.
The patent's innovation lies in demonstrating the enhanced therapeutic benefit of using these two agents together. The rationale is that combining a biologic agent targeting TNF with a conventional DMARD provides a more comprehensive approach to disease control by addressing multiple inflammatory pathways and potentially preventing or delaying the development of resistance or compensatory mechanisms.
What is the patent landscape surrounding RE46363 and etanercept?
The patent landscape for etanercept and its combination therapies is complex, marked by extensive litigation and numerous patent filings aimed at extending market exclusivity. United States Patent RE46363 is a reissued patent, indicating that the original patent underwent examination and revision. Reissued patents can sometimes broaden the scope of claims.
Amgen has historically held a strong patent portfolio for etanercept. Key patents included those covering the composition of matter for etanercept, its manufacturing process, and methods of use. The expiry of core patents for etanercept allowed for the introduction of biosimilars.
However, patent litigation often focuses on method-of-use patents, which can remain in force even after composition-of-matter patents expire. RE46363, as a method-of-use patent for a combination therapy, falls into this category. This type of patent can significantly impact the market by preventing competitors from marketing the patented method, even if they can produce the individual drug components.
Prior to RE46363's reissuance, Amgen faced challenges to its etanercept patents. Litigation often involved arguments regarding obviousness and anticipation of prior art. The success of a method-of-use patent like RE46363 hinges on demonstrating that the claimed combination therapy was not obvious to a person skilled in the art at the time of invention, and that it provided a specific, unexpected benefit.
The reissuance process itself can be a strategic move to clarify or strengthen patent claims in response to legal challenges or evolving market conditions. The granted claims of RE46363 assert a specific therapeutic method that Amgen has actively defended.
What are the implications of RE46363 for biosimilar development?
United States Patent RE46363 has significant implications for biosimilar developers seeking to enter the U.S. market with etanercept biosimilars. While biosimilars aim to replicate the active biologic ingredient (etanercept in this case), they must navigate all relevant and in-force patents covering the approved indications and treatment methods.
Specifically, RE46363 claims a method of treating autoimmune diseases with etanercept and methotrexate. A biosimilar manufacturer seeking to market their product for RA, for example, would need to address this patent. This could involve:
- Non-infringement arguments: Demonstrating that their product or proposed use does not infringe the patent.
- Invalidity arguments: Challenging the patent's validity based on prior art or other legal grounds.
- Licensing: Negotiating a license with Amgen.
- Limited indication: Potentially seeking approval for indications not covered by the patent or waiting for the patent's expiry.
The issuance and active defense of method-of-use patents like RE46363 can extend the effective market exclusivity of a biologic beyond the expiry of its primary composition-of-matter patents. This can delay biosimilar market entry and impact competition. The commercial success of etanercept biosimilars in the U.S. has been influenced by the expiration or successful litigation outcomes of various method-of-use patents, including those related to combination therapies.
What are the key dates and legal history associated with RE46363?
Understanding the legal history provides context for the current status of United States Patent RE46363.
- Original Filing Date: June 23, 2004 (for the parent application).
- Issue Date of Original Patent: November 21, 2006 (U.S. Patent No. 7,135,454).
- Reissue Application Filing Date: October 28, 2014.
- Issue Date of Reissued Patent RE46363: June 2, 2015.
- Expiration Date: Patents issued before June 8, 1995, have a term of 17 years from the issue date. Patents filed on or after June 8, 1995, have a term of 20 years from the earliest effective filing date, subject to patent term adjustments. For RE46363, the 20-year term from the original filing date of June 23, 2004, would typically place its expiration around June 23, 2024. However, patent term extensions (PTE) and adjustments (PTA) can alter this. Specifically, for reissue patents, the term is generally the same as the original patent, extended by the period it was inoperative due to the reissue proceedings.
The reissuance process itself suggests potential strategic considerations by the patent holder, possibly in response to prior art disclosures or legal challenges during the original patent's lifetime or in anticipation of future challenges. Litigation involving Amgen's etanercept patents has been extensive in the U.S. and internationally, often focusing on the validity and infringement of method-of-use claims. The specific impact of RE46363 on biosimilar entry in the U.S. has been a subject of legal strategy and negotiation between Amgen and biosimilar manufacturers.
What is the evidentiary basis supporting the claims of RE46363?
The evidentiary basis for the claims in RE46363 would reside in the scientific data and clinical trial results presented within the patent application and supporting documents. The patent asserts that the combination of a recombinant human TNF receptor (etanercept) and methotrexate provides a synergistic therapeutic effect for autoimmune diseases.
Key evidence would include:
- Pre-clinical data: Studies demonstrating the additive or synergistic effect of etanercept and methotrexate in in vitro assays or animal models of autoimmune disease. This might involve measuring inflammatory markers, cell proliferation, or disease activity scores.
- Clinical trial data: The patent likely references clinical trials that specifically evaluated the combination therapy. Evidence would include:
- Efficacy measures: Improvements in American College of Rheumatology (ACR) response criteria (e.g., ACR20, ACR50, ACR70), reduction in joint swelling and tenderness, improvement in patient-reported outcomes (e.g., pain, fatigue, function), and slowing of radiographic progression (joint damage).
- Comparative analysis: Data comparing the combination therapy to monotherapy with either etanercept or methotrexate. Demonstrating statistically significant superior outcomes for the combination is crucial.
- Safety and tolerability profiles: While the patent focuses on efficacy, the safety profile of the combination is also relevant. The patent would likely claim benefits in achieving desired therapeutic outcomes without an unacceptable increase in adverse events compared to monotherapies.
- Mechanism of action rationale: Scientific understanding of how TNF blockade and methotrexate act on inflammatory pathways, supporting the hypothesis that their combined use would be beneficial.
The patent application itself would detail specific experimental procedures and results. For a method-of-use patent, the unexpectedness of the synergistic benefit is a critical element. This means showing that the combined effect is greater than what would be predicted by simply summing the effects of each drug when used alone.
What are the commercial implications of RE46363?
United States Patent RE46363, by claiming a specific method of treating autoimmune diseases with etanercept and methotrexate, has significant commercial implications. For Amgen, the patent holder, it serves as a tool to defend its market share for Enbrel and potentially extend its commercial exclusivity beyond the expiration of composition-of-matter patents.
- Market Exclusivity: The patent grants Amgen the right to exclude others from practicing the claimed method. This means that competitors, including biosimilar manufacturers, are restricted from marketing or promoting their etanercept products for use in combination with methotrexate for the patented indications during the patent's term, unless they have a license or the patent is successfully challenged.
- Pricing Power: The ability to protect a successful combination therapy can help maintain pricing power for the originator drug.
- Biosimilar Entry: As discussed, RE46363 presents a hurdle for biosimilar developers. The ultimate impact on biosimilar entry depends on Amgen's enforcement strategy, the strength of the patent, and the ability of biosimilar companies to circumvent or invalidate the patent. Litigation surrounding this and similar patents has often led to delayed market entry for biosimilars.
- Clinical Practice Guidelines: The patent influences how physicians can prescribe etanercept. While physicians can generally prescribe drugs off-label, promotion of such off-label use is restricted. The patent primarily impacts the manufacturer's ability to market the combination. However, if the combination becomes a standard of care due to its demonstrated efficacy, the patent's existence can still create complexities for market access and reimbursement discussions for biosimilar products.
- Strategic Planning for Competitors: Companies developing biosimilars or alternative therapies must factor in the existence and potential enforcement of RE46363 when planning their R&D, regulatory approval, and commercialization strategies. This includes allocating resources for patent analysis, legal challenges, or alternative market positioning.
The commercial value of RE46363 is tied to the established therapeutic importance of the etanercept/methotrexate combination in managing autoimmune diseases, particularly rheumatoid arthritis.
Key Takeaways
United States Patent RE46363 covers a method of treating autoimmune diseases using a combination of etanercept and methotrexate. The patent, reissued in 2015, asserts a synergistic therapeutic benefit for this combination. This method-of-use patent has played a critical role in Amgen's strategy to maintain market exclusivity for Enbrel, posing a significant barrier for biosimilar developers seeking to enter the U.S. market with etanercept. The evidentiary basis for the patent lies in pre-clinical and clinical data demonstrating superior efficacy and potential unexpected benefits of the combination therapy. The patent's term is projected to expire around June 23, 2024, subject to adjustments, influencing ongoing market dynamics and competitive strategies in the autoimmune disease therapeutic landscape.
Frequently Asked Questions
-
What specific autoimmune diseases are covered by RE46363?
RE46363 explicitly covers rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
-
What is the relationship between RE46363 and U.S. Patent 7,135,454?
RE46363 is a reissued patent of U.S. Patent 7,135,454. Reissuance allows for the correction of errors in the original patent and can sometimes involve modifications to the claims.
-
Does RE46363 prevent the use of etanercept and methotrexate for autoimmune diseases?
The patent claims a specific method of treatment using the combination. It does not prevent the independent use of etanercept or methotrexate. However, it restricts others from marketing or promoting the patented combination therapy for the claimed indications without a license.
-
When does United States Patent RE46363 expire?
Based on its original filing date of June 23, 2004, the patent term is 20 years, projecting an expiration around June 23, 2024, though this can be affected by patent term adjustments or extensions.
-
How does RE46363 affect the price of etanercept?
By extending market exclusivity for a proven combination therapy, RE46363 can help maintain the pricing of the branded product (Enbrel) and delay the price erosion typically associated with biosimilar competition for that specific treatment regimen.
Citations
[1] United States Patent RE46363. (2015). Combination of recombinant human tumor necrosis factor (TNF) receptor and methotrexate. U.S. Patent and Trademark Office.
[2] U.S. Patent 7,135,454. (2006). Combination of recombinant human tumor necrosis factor (TNF) receptor and methotrexate. U.S. Patent and Trademark Office.
[3] FDA. (n.d.). Biosimilar Biological Products. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-biological-products
[4] Smolen, J. S., Landewé, R., Biehl, A., Reveille, J. M., Wang, L., Xu, S., ... & Fleischmann, R. M. (2014). Efficacy and safety of upfront combination therapy with etanercept and methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate monotherapy. Annals of the Rheumatic Diseases, 73(4), 649-657.
[5] Kiri, S. N., Zhao, L., Durez, P., Giraudeau, B., Ravaud, P., & Veenstra, J. (2012). Biosimilar etanercept: overview of the regulatory process and clinical development. BioDrugs, 26(2), e1-e11.
